Chronic Myeloid Leukemia (CML)

  • Registration Closed

[none]

Neil Shah, MD, PhD

UCSF Comprehensive Cancer Center

Neil P. Shah, MD, PhD, received his BS from the University of California, Berkeley, and his MD and PhD degrees from the UCLA School of Medicine. He remained at UCLA for his Internship and Residency training in Internal Medicine, as well as his fellowship training in Hematology and Oncology. He performed postdoctoral research in the laboratory of Charles Sawyers, where his translational studies led directly to the clinical investigation and FDA approval of dasatinib, a transformative therapy for patients with chronic myeloid leukemia (CML).

He joined the faculty at UCSF in 2006, and is presently the Edward S. Ageno Distinguished Professor in Hematology/Oncology at the University of California, San Francisco School of Medicine. He also serves as Leader of the Hematopoietic Malignancies Program within the Helen Diller Family Comprehensive Cancer Center at UCSF, and Director of the UCSF Molecular Medicine Residency Program. He is an internationally known as an expert in targeted therapy for CML. His laboratory efforts remain firmly rooted in molecular studies of human leukemias and attempts to translate expanding knowledge of the genetics of these diseases toward the development of more active and better tolerated targeted therapeutics. 

Key:

Complete
Failed
Available
Locked
Virtual Session
09/12/2020 at 2:00 PM (EDT)   |  45 minutes
09/12/2020 at 2:00 PM (EDT)   |  45 minutes